Press release
Verastem Oncology to Present at the Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer,
About this update from Verastem, Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nVerastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening beginning Thursday, November 18, 2021 at 8:00 a.m. GMT (3:00 a.m. ET).\n\nA webcast of the presentation will be available on investors section of the Company’s website at www.verastem.com. An archived presentation will be made available for 30 days.\n\nAbout Verastem Oncology\n\nVerastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211111005376/en/\n\nInvestors:\nAjay Munshi\nVice President, Corporate Development\n+1 781-469-1579\[email protected]\n\nSherri Spear\nArgot Partners\n+1 212-600-1902\[email protected]\n\nMedia:\nLisa Buffington\nCorporate Communications\n+1 781-292-4205\[email protected]\n\nSource: Verastem Oncology","length":3143,"tagName":"div"}]